Data for the Boehringer Ingelheim GmbH/Zealand Pharma A/S drug candidate survodutide (BI 456906) presented at the American Diabetes Association (ADA) annual meeting in San Diego showed that at the highest dose of 4.8mg once weekly, patients who were overweight or obese and who remained on treatment for the full 46 weeks of the companies’ Phase II clinical trial achieved 18.7% weight loss, potentially offering an additional option for doctors prescribing GLP-1-targeting medicines.
Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss
Drug Targets GLP-1 And Glucagon Receptors
Survodutide provides another obesity treatment option, albeit with gastrointestinal side effects that will need to be managed with slow titration to maintenance dosing, which will be tested in Phase III.